Form D · Biotechnology
Seaport Therapeutics, Inc.
Boston, MA · CIK 0002042347
Offering snapshot reported Oct 31, 2024 · SEC filing
- Reported sold
- $226M Offering amount: $226M
- Investors reported
- 33 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 18, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 31, 2024 | Initial | $225,899,940 | No comparison | 33 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-528276
Source: Form D, filed Oct 31, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael Chen | Executive |
| Bharatt Chowrira | Director |
| Eric Elenko | Director |
| Lana Gladstein | Executive |
| Eric Green | Executive |
| James I. Healy | Director |
| Antony Loebel | Executive |
| Robert Nelsen | Director |
| Steven Paul | Director |
| Jason Pitts | Director |
| Denice Torres | Director |
| David Wheadon | Director |
| Daphne Zohar | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
6 Tide Street Suite 400
Boston, MA, 02110
Boston, MA, 02110